Innovation Center for Cell Therapy
Kangnan Road, Pudong New Area
1,260 m² BSL-2 Cell Biology Laboratory/1,650 m² GMP-IMP Clinical Supply Base
-
Early Stage R&D
Core Technology Platforms
Pipeline Layout+ Early R&D Projects + Innovative Platform Technologies
-
Pharmaceutical Development
GMP-IMP Clinical Trial Supply Manufacturing Base
Product Process + Analytical Methods+ Process Innovation & Technical Upgrading
-
Clinical Translation
Central Laboratory Platform
Translational Medicine + Exploratory Human Trials
R&D pipeline
Oncology
Non-Oncology
| Mechanism | Product | Indications | Preclinical | IND | Phase I | Phase II/III | NDA | Approved for Marketing |
| Autologous CAR-T | FKC876 | Large B-cell Lymphoma (3L+) | ||||||
| Large B-cell Lymphoma (3L+) | ||||||||
| Follicular Lymphoma | ||||||||
| FKC889 | Mantel Cell Lymphoma | |||||||
| Acute Lymphoblastic Leukemia | ||||||||
| FKC289 | Autoimmune Diseases | |||||||
| Autoimmune Diseases | ||||||||
| Autoimmune Diseases | ||||||||
| FKC516 | Large B-cell Lymphoma | |||||||
| FKC118 | Large B-cell Lymphoma | |||||||
| In-vivo CAR-T | FKC399 | Autoimmune Diseases | ||||||
| Universal CAR-T | FKC389 | Hematological Malignancies, Autoimmune Diseases | ||||||
| Stem Cell Therapy | FKC929 | Knee Osteoarthritis |
Fosun Kairos 10-Year Outlook
2023
In June 2023, a new indication for YIKAIDA was approved for marketing
2025
Continuously strengthening the pipeline
2030
7-8 products launched